Mobile messaging support versus usual care for people with type 2 diabetes on clycemic control: Protocol for a multicenter randomized controlled trial

التفاصيل البيبلوغرافية
العنوان: Mobile messaging support versus usual care for people with type 2 diabetes on clycemic control: Protocol for a multicenter randomized controlled trial
المؤلفون: Moffat J. Nyirenda, Kirsty Bobrow, Naomi S. Levitt, Emmanuelle Daviaud, Hazel Namadingo, Lionel Tarassenko, Sara Cooper, Enita Phiri, John Prince, Shane A. Norris, Jonathan Ngoma, Donela Besada, David Springer, Andrew Farmer, Ly-Mee Yu, Nicola Williams, Amelia C. Crampin, Natalie Leon, Bruno Pauly
المصدر: JMIR Research Protocols
بيانات النشر: JMIR Publications, 2019.
سنة النشر: 2019
مصطلحات موضوعية: Short Message Service, 020205 medical informatics, Psychological intervention, 02 engineering and technology, treatment adherence, law.invention, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, law, Intervention (counseling), Health care, 0202 electrical engineering, electronic engineering, information engineering, Protocol, Medicine, 030212 general & internal medicine, mobile health, Glycemic, Protocol (science), Data collection, business.industry, General Medicine, medicine.disease, randomized controlled trial, diabetes mellitus, Medical emergency, type 2 diabetes, business
الوصف: Background: Health outcomes for people treated for type 2 diabetes could be substantially improved in sub-Saharan Africa. Failure to take medicine regularly to treat diabetes has been identified as a major problem. Resources to identify and support patients who are not making the best use of medicine in low- and middle-income settings are scarce. Mobile phones are widely available in these settings, including among people with diabetes; linked technologies, such as short message service (SMS) text messaging, have shown promise in delivering low-cost interventions efficiently. However, evidence showing that these interventions will work when carried out at a larger scale and measuring the extent to which they will improve health outcomes when added to usual care is limited.\ud \ud Objective: The objective of this trial is to test the effectiveness of sending brief, automated SMS text messages for improving health outcomes and medication adherence in patients with type 2 diabetes compared to an active control.\ud \ud Methods: We will carry out a randomized trial recruiting from clinics in two contrasting settings in sub-Saharan Africa: Cape Town, South Africa, and Lilongwe, Malawi. Intervention messages will advise people about the benefits of their diabetes treatment and offer motivation and encouragement around lifestyle and use of medication. We allocated patients, using randomization with a minimization algorithm, to receive either three to four intervention messages per week or non-health-related messages every 6 weeks. We will follow up with participants for 12 months, measuring important risk factors for poor health outcomes and complications in diabetes. This will enable us to estimate potential health benefits, including the primary outcome of hemoglobin A1c (HbA1c) levels as a marker for long-term blood glucose control and a secondary outcome of blood pressure control. We will record the costs of performing these activities and estimate cost-effectiveness. We will also use process evaluation to capture the collection of medication and assess the reception of the intervention by participants and health care workers.\ud \ud Results: Recruitment to the trial began in September 2016 and follow-up of participants was completed in October 2018. Data collection from electronic health records and other routinely collected sources is continuing. The database lock is anticipated in June 2019, followed by analysis and disclosing of group allocation.\ud \ud Conclusions: The knowledge gained from this study will have wide applications and advance the evidence base for effectiveness of mobile phone-based, brief text messaging on clinical outcomes and in large-scale, operational settings. It will provide evidence for cost-effectiveness and acceptability that will further inform policy development and decision making. We will work with a wide network that includes patients, clinicians, academics, industry, and policy makers to help us identify opportunities for informing people about the work and raise awareness of what is being developed and studied.\ud \ud Trial Registration: ISRCTN Registry ISRCTN70768808; http://www.isrctn.com/ISRCTN70768808Test (Archived by WebCite at http://www.webcitation.org/786316ZqkTest)\ud \ud International Registered Report Identifier (IRRID): DERR1-10.2196/12377
وصف الملف: application/pdf
تدمد: 1929-0748
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a4ba7ea7cc2ac98c6d53dea620b4ce7Test
https://ora.ox.ac.uk/objects/uuid:52783105-25c4-47f7-86eb-e182362bda38Test
حقوق: OPEN
رقم الانضمام: edsair.doi.dedup.....1a4ba7ea7cc2ac98c6d53dea620b4ce7
قاعدة البيانات: OpenAIRE